<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Diabetic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> is characterised by diastolic dysfunction, <z:mp ids='MP_0003674'>oxidative stress</z:mp>, <z:mp ids='MP_0003045'>fibrosis</z:mp>, <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and pathological cardiomyocyte <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="16749">Phosphoinositide</z:chebi> 3-kinase (PI3K)(p110α) is a cardioprotective kinase, but its role in the diabetic heart is unknown </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to assess whether PI3K(p110α) plays a critical role in the induction of diabetic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>, and whether increasing PI3K(p110α) activity in the heart can prevent the development of cardiac dysfunction in a setting of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> was induced with <z:chebi fb="1" ids="9288">streptozotocin</z:chebi> in adult male cardiac-specific transgenic mice with increased PI3K(p110α) activity (constitutively active PI3K [p110α], caPI3K] or decreased PI3K(p110α) activity (dominant-negative PI3K [p110α], dnPI3K) and non-transgenic (Ntg) mice for 12 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>Cardiac function, histological and molecular analyses were performed </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Diabetic Ntg mice displayed diastolic dysfunction and increased cardiomyocyte size, expression of atrial and B-type natriuretic <z:chebi fb="7" ids="16670">peptides</z:chebi> (Anp, Bnp), <z:mp ids='MP_0003045'>fibrosis</z:mp> and <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, as well as increased <z:chebi fb="1" ids="18421">superoxide</z:chebi> generation and increased protein kinase C β2 (PKCβ2), p22 ( phox ) and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> signal-regulating kinase 1 (Ask1) expression </plain></SENT>
<SENT sid="6" pm="."><plain>Diabetic dnPI3K mice displayed an exaggerated <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> phenotype compared with diabetic Ntg mice </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, diabetic caPI3K mice were protected against diastolic dysfunction, pathological cardiomyocyte <z:mpath ids='MPATH_159'>hypertrophy</z:mpath>, <z:mp ids='MP_0003045'>fibrosis</z:mp> and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>Protection in diabetic caPI3K mice was associated with attenuation of left ventricular <z:chebi fb="1" ids="18421">superoxide</z:chebi> generation, attenuated Anp, Bnp, PKCβ2, Ask1 and p22 ( phox ) expression, and elevated AKT </plain></SENT>
<SENT sid="9" pm="."><plain>Further, in cardiomyocyte-like cells, increased PI3K(p110α) activity suppressed high <z:chebi fb="105" ids="17234">glucose</z:chebi>-induced <z:chebi fb="1" ids="18421">superoxide</z:chebi> generation and enhanced <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS/INTERPRETATION: These results demonstrate that reduced PI3K activity accelerates the development of diabetic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>, and that enhanced PI3K(p110α) activity can prevent adverse cardiac remodelling and dysfunction in a setting of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>